ARIAD Announces Support of Patients with Resistant or Intolerant CML Through Its Donation to Chronic Disease Fund

CAMBRIDGE, Mass.--()--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it had made a donation to the Chronic Disease Fund (CDF) in support of patients with chronic myeloid leukemia (CML) who are resistant or intolerant to prior therapy. CDF is an independent non-profit charitable organization that helps eligible patients with chronic diseases, cancer and other life-altering conditions obtain the life-saving medications they need. Through ARIAD’s contribution, the organization will provide financial assistance to eligible patients with resistant or intolerant CML who require help paying their out-of-pocket expenses, including co-pays or co-insurance. CDF will determine the distribution of these funds and patient eligibility.

“Approximately 5,000 new cases of CML are diagnosed each year in the United States, and over time, many of these patients will develop resistance or intolerance to tyrosine kinase inhibitors,” said Marty Duvall, senior vice president, commercial operations at ARIAD. “ARIAD is dedicated to helping these refractory or intolerant patients receive the medications they need, and we are proud to support the CDF as it assists patients.”

In addition, ARIAD has a patient assistance and support program designed to help healthcare professionals or patients access, afford and adhere to treatment. Information on the ARIAD PASS™ program for patient assistance is available by calling 1-855-447-PASS (855-447-7277) or visiting www.ARIADPASS.com.

About ARIAD

ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines. ARIAD is working on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer and other difficult-to-treat cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. For additional information, visit http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).

Contacts

ARIAD Pharmaceuticals, Inc.
For Investors:
Kendra Adams, 617-503-7028
Kendra.adams@ariad.com
or
For Media:
Liza Heapes, 617-621-2315
Liza.heapes@ariad.com

Sharing

Contacts

ARIAD Pharmaceuticals, Inc.
For Investors:
Kendra Adams, 617-503-7028
Kendra.adams@ariad.com
or
For Media:
Liza Heapes, 617-621-2315
Liza.heapes@ariad.com